(19)
(11) EP 3 931 349 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
15.01.2025 Bulletin 2025/03

(45) Mention of the grant of the patent:
11.12.2024 Bulletin 2024/50

(21) Application number: 20763347.0

(22) Date of filing: 28.02.2020
(51) International Patent Classification (IPC): 
C12Q 1/6886(2018.01)
A61K 31/337(2006.01)
A61P 43/00(2006.01)
A61K 31/195(2006.01)
A61K 45/06(2006.01)
(52) Cooperative Patent Classification (CPC):
A61P 43/00; A61K 31/195; A61K 45/06; A61K 31/337; C12Q 1/6886; C12Q 2600/156
 
C-Sets:
  1. A61K 31/337, A61K 2300/00;
  2. A61K 31/195, A61K 2300/00;

(86) International application number:
PCT/US2020/020349
(87) International publication number:
WO 2020/176846 (03.09.2020 Gazette 2020/36)

(54)

APOE GENOTYPING IN CANCER PROGNOSTICS AND TREATMENT

APOE-GENOTYPING IN DER KREBSPROGNOSE UND -THERAPIE

GÉNOTYPAGE APOE DANS LE PRONOSTIC ET LE TRAITEMENT DU CANCER


(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 28.02.2019 US 201962811575 P

(43) Date of publication of application:
05.01.2022 Bulletin 2022/01

(73) Proprietors:
  • The Rockefeller University
    New York, NY 10065 (US)
  • Inspirna, Inc.
    Long Island City, NY 11101 (US)

(72) Inventors:
  • TAVAZOIE, Sohail F.
    New York, NY 10065 (US)
  • OSTENDORF, Benjamin N.
    New York, NY 10021 (US)
  • TAVAZOIE, Masoud
    New York, NY 10065 (US)
  • GONSALVES, Foster
    Brooklyn, NY 11238 (US)

(74) Representative: Barker Brettell LLP 
100 Hagley Road Edgbaston
Birmingham B16 8QQ
Birmingham B16 8QQ (GB)


(56) References cited: : 
WO-A1-2015/065505
WO-A1-95/16791
WO-A2-2017/181163
CN-A- 109 251 974
US-A1- 2006 160 079
US-A1- 2015 065 515
US-A1- 2017 066 791
WO-A1-2017/161188
WO-A2-2014/028461
CN-A- 108 738 323
US-A- 5 945 289
US-A1- 2012 231 457
US-A1- 2015 150 941
US-A1- 2018 072 810
   
  • BENN MARIANNE ET AL: "Low-Density Lipoprotein Cholesterol and the Risk of Cancer: A Mendelian Randomization Study", JOURNAL OF THE NATIONAL CANCER INSTITUTE, vol. 103, no. 6, 1 February 2011 (2011-02-01), GB, pages 508 - 519, XP055972059, ISSN: 0027-8874, DOI: 10.1093/jnci/djr008
  • SPEIDELL ANDREW P ET AL: "Development of a HumanAPOEKnock-in Mouse Model for Study of Cognitive Function After Cancer Chemotherapy", NEUROTOXICITY RESEARCH, HARWOOD ACADEMIC PUBLISHERS, LAUSANNE, CH, vol. 35, no. 2, 4 October 2018 (2018-10-04), pages 291 - 303, XP036674838, ISSN: 1029-8428, [retrieved on 20181004], DOI: 10.1007/S12640-018-9954-7
  • CHANG N W ET AL: "Apolipoprotein E4 allele influences the response of plasma triglyceride levels to tamoxifen in breast cancer patients", CLINICA CHIMICA ACTA, ELSEVIER BV, AMSTERDAM, NL, vol. 401, no. 1-2, 1 March 2009 (2009-03-01), pages 144 - 147, XP025898593, ISSN: 0009-8981, [retrieved on 20081211], DOI: 10.1016/J.CCA.2008.12.005
  • SIMONS KARIN H ET AL: "T cell co-stimulation and co-inhibition in cardiovascular disease: a double-edged sword", NATURE REVIEWS CARDIOLOGY, NATURE PUBLISHING GROUP, GB, vol. 16, no. 6, 15 February 2019 (2019-02-15), pages 325 - 343, XP036784140, ISSN: 1759-5002, [retrieved on 20190215], DOI: 10.1038/S41569-019-0164-7
  • FYMAT ALAIN: "Harnessing the Immune System to Treat Cancers and Neurodegenerative Diseases", 4 April 2018 (2018-04-04), XP055853404, Retrieved from the Internet <URL:https://asclepiusopen.com/clinical-research-in-neurology/volume-1-issue-1/8.pdf> [retrieved on 20211021]
  • YANG ET AL.: "Causal relevance of circulating high-density lipoprotein cholesterol with cancer: a Mendelian randomization meta-analysis", SCI REP, vol. 5, no. 9495, 30 March 2015 (2015-03-30), pages 9495, XP055764108
  • TAVAZOIE ET AL.: "LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer", CELL, vol. 172, no. 4, 11 January 2018 (2018-01-11), pages 825 - 840, XP085347108
  • VERGHESE ET AL.: "ApoE influences amyloid-.beta. (A.beta.) clearance despite minimal apoE/A.beta. association in physiological conditions", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 110, no. 19, 7 May 2013 (2013-05-07), pages E1807 - E1816, XP055485641
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).